QF-Pro technology is now available through a partnership between Quilaban and HAWK Biosystems, expanding access to advanced protein analysis solutions.
Quilaban strengthens its portfolio in the field of research and protein analysis with the provision of QF-Pro technology in Portugal. This solution, developed by HAWK Biosystems, enables more detailed functional analysis of proteins directly in tissue context.
Unlike traditional approaches, this technology makes it possible not only to identify proteins present in cells, but also to understand their functional behaviour, contributing to a more precise reading of disease-associated mechanisms. This capability is particularly relevant in the identification of biomarkers and in the assessment of treatment response.
“The possibility of quantifying functional states of proteins directly in tissue context opens new opportunities to understand disease mechanisms and identify biomarkers with greater precision”, explains Sónia Pereira, Product and Applications Manager at Quilaban.
In a context where fields such as oncology and precision medicine require increasingly targeted and effective approaches, tools of this type can play an important role in supporting the development of therapies more tailored to each patient’s needs. In this way, it becomes possible to reduce less efficient approaches and support more informed decisions at clinical and scientific level.
The provision of QF-Pro in Portugal reinforces laboratories’ and research centres’ access to advanced protein analysis solutions. Simultaneously, this partnership reflects Quilaban’s commitment to promoting scientific innovation and supporting the evolution of biomedical research and diagnostics.
